Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoGlio: Neoadjuvant Chemoradiation for Glioblastoma
NCT04209790Phase 2
Key facts
- Status
- Terminated
- Start
- Apr 2020
- Primary completion
- Sep 2022
- Countries
- 1
- Sponsor
- Geisinger
- Modality
- Small Molecules
- Drugs
- temozolomide
- Conditions
- glioblastoma (GBM)
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in glioblastoma (GBM), sponsored by Geisinger. Primary endpoints: No Study Related Undue Toxicity or Progression at 7 months and Progression Free Survival. Started Apr 2020; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Neoadjuvant chemoradiation and surgical resection
Neoadjuvant Temozolomide + Radiation followed by Surgery
03
Who it enrols
Newly diagnosed GBM patients suitable for resection with KPS > 70 and adequate organ function.
04
Endpoints
Primary
No Study Related Undue Toxicity or Progression
Progression Free Survival
Beyond the preview
Go deeper on NCT04209790.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209790.